Background & Summary
====================

Suicide is the 10th leading cause of mortality in the world^[@b1],[@b2]^. It is a complex, multifactorial behavioural condition in which proximal and distant risk factors, such as mental disorders, genetic and epigenetic factors, social, cultural and economic environment, gender, age, personality, eating disorders, as well as drug or alcohol abuse^[@b3]^ play important roles. The presence of early child abuse has also been described as a contributing factor to suicidal behaviour^[@b8]^. Studies have repeatedly shown that suicide is most common among patients with mood disorders, such as major depressive disorder and bipolar disorder^[@b9]^.

Whole-exome sequencing (WES) is a cost-effective and powerful tool for the analysis of complex and rare genetic diseases^[@b10]^. WES technique allows a base-pair comparison of exomes and consequently the examination of rare genetic variants, which may play a role in suicide. Alterations in copy number variations (CNVs) and short-tandem repeats (STRs), as well as the viral infections can be also analysed by WES.

We performed high-depth, paired-end, short-read WES on 23 suicide victims suffered from major depressive disorder (MDD; this information is available in EGA sample metadata) and 21 control patients who died from other diseases (EGA sample metadata). Harvesting of brain tissues was approved by the local ethics committee^[@b11]^. Informed consents from the next kin have not been obtained from the victims because the local regulations did not require consent for autopsy. All data were handled anonymously. Both of the cohorts were of Hungarian ethnicity. The Hungarian population is known to have had a very high annual suicide rate in the previous century^[@b12],[@b13]^. The DNA samples derived from post-mortem brains were sequenced using the Agilent SureSelectXT Human All Exon V5 + UTRs kit and Illumina HiSeq 2000 sequencing platform resulting in an average of 117 million paired-end reads.

We obtained very high coverage per base position in both cohorts; in the suicide cohort 95.4--97.5% (quartiles) of target regions had higher than 20-fold and 82.8--90.5% of target regions had higher than 40-fold coverage. In the Hungarian control cohort these values were 96.3--97.5% for 20-fold and 81.6--91.6% for 40-fold coverage, respectively. We called on average \~130,000 variants per sample. Altogether we observed 442,270 unique variants in the control and suicide cohorts. Furthermore, we determined a total of 320,976 single nucleotide variants (SNVs) and 47,313 insertions/deletions (indels).

The library preparation kit used in this study, as well as the obtained very high coverage of sequencing reads that we obtained enabled us to capture information not only about the exons but also about the 5′- and 3′-UTRs, the promoters to a certain length, and even about off-target sequences, such as introns, intergenic regions and infecting viruses. Our dataset had 286,754 high coverage regions (exceeding 20-fold coverage) in all samples that can be suitable for downstream analysis of CNVs.

Here we describe the sample collection methods, the library preparation and sequencing method, the currently available data records, and technical validations for our dataset. A schematic overview of this study, including the experimental procedure and the bioinformatics workflow, is also presented ([Fig. 1](#f1){ref-type="fig"}).

To our knowledge, this dataset is the first individual-level, open-access WES data release targeted to suicide. The dataset described here has been thoroughly analysed in our related manuscript^[@b6]^, where it has been shown that the TGF-β signalling pathway and three voltage-gated calcium ion channels may play an important role in the pathogenesis of suicidal behaviour. Our analysis proposed that suicide may be an umbrella-disease like disorder.

Here we provide the processed BAM files, as well as the processed Variant Call format (VCF) files for each of the samples containing the analysis ready variants of GATK HaplotypeCaller pipeline that allows for the testing of different variant filtration strategies that we had used in our original manuscript or for hypothesis testing of candidate genes (covered by SureSelect V5 All Exon plus UTR kit) without tedious bioinformatic processing.

Our dataset provided here in this manuscript can be re-used to investigate suicide and MDD. These data can be a valuable resource for investigating genetic variants, genes and signalling pathways to identify novel factors related to these disorders, and may provide novel information for the investigation of the Hungarian population or in general for studies of genetic polymorphisms of human population.

Methods
=======

The methods described here are an expanded version of those described in our recently published, related publication^[@b6]^.

Medical history of the suicide victims
--------------------------------------

This study is based on whole-genome sequence data from occipital, cerebellar and somatomotor cortex regions of the brains of 23 suicide victims (15 males and 8 females) and 21 control patients (14 males and 7 females) who died suddenly from other causes (this information is available in EGA sample metadata). Samples were obtained by autopsy at the Department of Forensic Medicine of the Semmelweis University Medical School. For all of the suicide victims, a psychiatric diagnosis of major depression was on record. The diagnoses had been made by experienced psychiatrists on the basis of Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV). Patients with a history of schizophrenia, epilepsy and other disorders were excluded from the study. The medical, psychiatric, and drug history of the suicide victims was obtained by psychological autopsy, which included interviews with the attending physician and with family members, as well as data obtained from medical records. The participants included in this study had no history of drug or alcohol abuse, and had not used antidepressant medication for at least two months prior to death. This information was confirmed by toxicology tests on blood samples. Suicide victims died by hanging (n = 16), drug overdose (n = 6), or jumping from height (n = 1). Causes of death in control subjects are presented in EGA sample metadata. Harvesting of tissues was approved by the local ethics committee.

Tissue collection, dissection, and storage
------------------------------------------

Brains were obtained 1 to 10 h after death (this information is available in EGA sample metadata). After removal from the skull, the brains were cut in six major pieces (four cortical lobes, basal ganglia -- diencephalon, and lower brain stem -- cerebellum), rapidly frozen on dry ice, and stored at −70 °C until dissection (2 days to 2 months). At the time of dissection, the brain samples were sliced into 1 mm-thick coronal sections at a temperature of 0 to 10 °C. The cortical areas were cut out of the sections by a fine microdissecting (Graefe's) knife. In all cases, cortical samples were always taken from the right hemisphere. The samples were stored in airtight containers or plastic tubes at −70 °C until further use.

DNA purification
----------------

Genomic DNA (gDNA) samples were isolated from the occipital, cerebellar or somatomotor cortex regions ([Table 1](#t1){ref-type="table"} (available online only)) using the DNeasy Blood and Tissue Kit (Qiagen) according to the manufacturer's recommendations for the spin-column protocol, using 30 mg staring tissue material from each sample. In short, tissue samples were cut into small pieces, and then lysis buffer (provided by the kit) and proteinase K were added. Lysis reactions were carried out at 56°C until complete lysis was obtained. DNeasy Mini spin columns (kit's component) were used for the isolation of gDNA from the lysate. Elution was carried out twice to a final volume of 100 μl per elution.

Quality and quantity check of DNA
---------------------------------

The quality of the DNA was checked prior to downstream analysis by NanoDrop (Thermo Fischer Scientific) measurement. High-quality samples with an OD 260/280 ratio ranging from 1.8 to 2.0 were subjected to the next step. Qubit 2.0 fluorometer (Invitrogene) was used for genomic DNA quantification before library preparation ([Table 1](#t1){ref-type="table"} (available online only)).

Whole-exome sequencing
----------------------

Paired-end, indexed libraries for Illumina sequencing were prepared from the DNAs of the 23 suicide victims and the 21 controls using post-mortem brain cortex tissues as a source. Whole-exome sequencing was carried out as previously described^[@b14]^ with slight modifications. In short, 200 ng from each of the qualified gDNA samples in 100 μl volume were sheared into fragments of approximately 200--450 bps in Covaris microTUBEs (Covaris microTUBE AFA Fiber Pre-Slit Snap-Cap 6 × 16 mm) with Covaris s220 high-performance ultrasonicator. The quality of the DNA was checked prior to downstream analysis, using the Agilent Bioanalyser 2100 (Agilent Technologies) and the High Sensitivity DNA Analysis Kit (Agilent Technologies; [Fig. 2](#f2){ref-type="fig"}). The end-repair, A-tailing (3′ adenylation) and ligation of the paired-end adaptors steps were executed with the Agilent SureSelect Human All Exon V5 + UTRs kit (Agilent Technologies) as was described in the following manual: SureSelect^XT^ Target Enrichment System for Illumina Paired-End Sequencing Library Illumina HiSeq and MiSeq Multiplexed Sequencing Platforms Protocol version 1.6 (SureSelect^XT^). Amplification of the adaptor-ligated libraries was performed using the Herculase II Fusion DNA polymerase (Agilent Technologies) following instructions as set forth in the above mentioned manual. Purification after the enzymatic reactions was carried out by using Agencourt AMPure XP beads (Beckman Coulter). Quality and quantity of the libraries were determined by 2100 Bioanalyser instrument and DNA 1000 Assay (Agilent Technologies; [Fig. 3](#f3){ref-type="fig"}). DNA library samples were hybridized with target-specific Capture Library using the SureSelect^XT^ Reagent Kit, HSQ for the HiSeq platform (Agilent Technologies) based on the SureSelect^XT^ protocol. Incubation of the hybridization mixture was carried out at 65 °C for 24 h. After hybridization, the targeted molecules were captured on streptavidin-coated magnetic beads. The SureSelect enriched libraries were amplified by PCR with 6-bp indexing primers ([Table 2](#t2){ref-type="table"} (available online only)) following the SureSelect^XT^ manual's post-capture PCR recommendations using 12 cycles. The amplified libraries were purified using AMPure XP beads. The quality and quantity of the indexed libraries were checked by Agilent Bioanalyser and High Sensitivity DNA Assay ([Fig. 4](#f4){ref-type="fig"}, [Table 3](#t3){ref-type="table"}). The quantities were also measured by Qubit 2.0 ([Table 3](#t3){ref-type="table"}). Two or three indexed libraries were pooled (Tables 2 (available online only) and [3](#t3){ref-type="table"}) and the pooled samples were sequenced in one lane of a HiSeq 2000 flow cell, generating 101 bp paired-end reads.

Sequence QC
-----------

Illumina HiSeq paired-end BCL files were converted to FASTQ files by the standard Illumina protocol (bcl2fastq) in order to remove the adapters, the known Illumina artefacts.

Read Mapping, BAM file post processing
--------------------------------------

The trimmed, adapter removed FASTQ files were mapped to the GRCh37 reference genome by the Burrows-Wheeler Aligner (version 0.7.9a-r786) with the BWA MEM paired-end mapping algorithm using the following parameters: -M -w 150 -d 80 -c 2000. This mapper is generally recommended for high-quality queries as it is fast, and it allows gapped alignments which are essential for the accurate identification of SNV and insertion/deletions (indels; <http://genestack-user-tutorials.readthedocs.io/tutorials/WES_data_analysis/index.html>). Duplicates were marked by the Picard tools (version 1.113) MarkDuplicates algorithm. The raw BAM files (Data Citation 1) were realigned and base quality recalibrated by Genome Analysis Toolkit (GATK version: 3.3-0-g37228af).

Sequence QC
-----------

FastQC (version v0.11.2) was used to generate quality reports (Data Citation 2) using the aligned and base quality recalibrated BAM files.

Variant calling
---------------

The variants were called by the GATK HaplotypeCaller (version: 3.3-0-g37228af) algorithm using the GVCF mode cohort analysis according to the Best Practice Guidelines^[@b15]^. Raw Variants were recalibrated by GATK VariantRecalibrator according to the best practice recommendations using the HapMap, Omni, dbSNP, 1000 G, Mills datasets for training included in the GATK GRCh37 bundle resulting analysis ready variants (Data Citation 2).

Data records
============

The raw FASTQ files, the GRCh37 aligned BAM files, and the variants in VCF 4.1 format associated with the samples analysed in this study are available on request at EGA (Data Citation 1). We also deposited the QC metric files of Picard MarkDuplicate, and QC reports of FastQC of the analysis ready Bam files at Figshare (Data Citation 2) and in [Supplementary Table 1](#S1){ref-type="supplementary-material"}.

Technical validation
====================

Quantitation of the purified DNA samples
----------------------------------------

The isolated DNA samples were quantified by Qubit (Life Technologies) fluorometer using Qubit dsDNA HS (High Sensitivity) Assay Kit, which is highly selective for double-stranded DNA over RNA and is designed to be accurate for initial sample concentration ranging from 10 pg/μl to 100 ng/μl. DNA samples were diluted to 4 ng/μl with 1X Low TE Buffer. NanoDrop (Thermo Fischer Scientific) measurements were also performed to assess quantity and quality of DNA, 260:280 and 260:230 ratios greater to 1.8 were accepted.

Quality control of the sheared DNA samples
------------------------------------------

The quality of the sheared DNA samples (200 ng of each) were checked prior to downstream analysis, using the Agilent Bioanalyser 2100 (Agilent Technologies), and High Sensitivity DNA chip and reagent kit. The electropherogram showed a DNA fragment size peak (for each of the samples) at around 150 bps ([Fig. 2](#f2){ref-type="fig"}).

Quality check of the amplified samples
--------------------------------------

Agilent Bioanalyser 2100 (Agilent Technologies) and DNA 1000 Assay were used for the quality and quantity control of the libraries after PCR. The sample fragments sizes were between 225 and 275 bps ([Fig. 3](#f3){ref-type="fig"}).

Assessment of the quantity and quality of the indexed library DNAs
------------------------------------------------------------------

The quality of the amplified, indexed libraries were determined before multiplexing using the Agilent Bioanalyser 2100 (Agilent Technologies) and High Sensitivity DNA Assay ([Table 3](#t3){ref-type="table"}). The peak of the DNA fragment size was between 200--450 bps for each of the samples with an average of 355 bps ([Fig. 4](#f4){ref-type="fig"}, [Table 3](#t3){ref-type="table"}).

Technical replicates
--------------------

Two independent technical replicate libraries were prepared and sequenced from the same patients (three suicide victims and two controls; [Table 4](#t4){ref-type="table"}).

Quality control of raw reads
----------------------------

Illumina BCL files were converted to FASTQ files by the standard Illumina protocol to remove low-quality reads and adaptors.

Quality control of mapped reads
-------------------------------

We used Picard tools MarkDuplicate algorithm to identify PCR or optical duplicates. According to MarkDuplicates statistics, we had very low percentages of duplicated reads (on average 0.624%) in our cohort. Genome Analysis Toolkit (GATK version 3.3) BaseRecalibrator base quality score recalibration tool was used to generate the final quality recalibrated BAM files for downstream analysis and variant calling according to best practices^[@b15]^. To check the quality of our mapped reads we used FastQC to generate quality reports of base quality score recalibrated BAM files. According to the FastQC reports we had no adapter contamination or overrepresented sequences indicating contamination in any of the analysed sequences. Furthermore, the majority of sequences were of high quality (average Phred quality score \>34) and even the last two base pairs of the sequences had an average Phred quality score \>30. On average 99.9% of reads were mapped, 99% were properly paired, and we had less than 0.1% singletons. The average read counts in the cohort were 117 013 694.9 while the average insert sizes were in the range of 157.7--190.0 base pairs ([Table 5](#t5){ref-type="table"} (available online only)). According to the main quality indicators of our dataset all data files fall within acceptable parameters as shown in [Table 5](#t5){ref-type="table"} (available online only).

Variant calling
---------------

The identification of different genomic variants including SNVs, indels, multiple nucleotide variants (MNVs), Genome Analysis Toolkit (GATK version 3.3) HaplotypeCaller algorithm was used with the GVCF mode cohort analysis according best practice^[@b15]^. HaplotypeCaller was run with the "-stand_emit_conf 10 -stand_call_conf 30" parameters. Variants were recalibrated by GATK VariantRecalibrator according to the best practice recommendations using the HapMap, Omni, dbSNP, 1000 G, Mills datasets for training included in the GATK GRCh37 bundle. We used 100.0, 99.9, 99.0, 90.0 tranches for variant recalibration and the 99.0 truth sensitivity level was used at ApplyRecalibration algorithm to identify QC PASS-ed variants.

Usage Notes
===========

Ethical approval for the study was obtained from the following institutional review boards:

The brain samples were collected by the Human Brain Tissue Bank (HBTB; Semmelweis University, Budapest). The activity of the HBTB has been authorized by the Committee of Science and Research Ethic of the Ministry of Health Hungary (ETT TUKEB: 189/KO/02.6008/2002/ETT) and the Semmelweis University Regional Committee of Science and Research Ethic (No. 32/1992/TUKEB) to remove human brain tissue samples, collect, store and use them for research.

The HBTB is a member of the BrainNet Europe II. consortium. The activity of the HBTB is in accordance with the ethic and safety rules and the scientific requirements of the consortium.

Human brain microdissection procedures were approved by the Regional and Institutional Committee of Science and Research Ethics of Scientific Council of Health (the number of the ethical license: 34/2002/TUKEB-13716/2013/EHR, Budapest, Hungary) and the Code of Ethics of the World Medical Association (Declaration of Helsinki).

Conducting genetic testing on tissue samples and then sending them abroad has been authorized by the Semmelweis University Regional Committee of Science and Research Ethics (No. 34/2002/TUKEB).

The Institutional Review Board (IRB) at Stanford has made the following determination about the activity of the study, titled "*Exome sequencing analysis of suicidal behavior using high-throughput DNA sequencing*", based on Office for Human Research Protections (OHRP) and Food and Drug Administration (FDA) regulations and guidance: this project does not require submission to the Stanford IRB, because the study does not involve human subjects, it is not about living individuals (NOT-H3 1/1; November 26, 2014).

The following explains how to access the dataset provided in this manuscript
----------------------------------------------------------------------------

The data is made available through the European Genome-phenome Archive (EGA). Search for the Data Access Committee (DAC) ID of our study (EGAD00001004184) at the homepage of EGA (<https://ega-archive.org/>). This will show detailed information on our dataset, data providers, DAC and any other related documentation. You can also find information about who to contact about access to this dataset. Access to data will be allowed to qualified researchers for appropriate health related studies.

A DAC group is responsible for the access of the datasets deposited in EGA.

Request for data access will be referred directly to our Data Access Committee: <https://ega-archive.org/datasets/EGAD00001004184>.

Data access decisions can be passed to the EGA in two ways: 1) By emailing helpdesk\@ega-archive.org with the email address of each applicant and confirmation of the dataset/s to provide access. The EGA will then create an EGA account with the relevant access permissions. 2) By using the EGA DAC Admin tools (available to DAC's dealing with more than 5 data access applications/month).

If you need to request access to this data set, please contact:

***DAC for Hungarian human exome team*** (Department of Medical Biology, University of Szeged, Hungary)

Contact person: Dr. Zsolt Boldogkői

Email: boldogkoi.zsolt\@med.u-szeged.hu

Applicants will be asked to complete the Data Access Agreement (DAA) (including a brief summary of the proposal, proposed usage of the dataset, the storage of data, so the DAC can determine if the planned usage falls within the consents) and to agree to the terms and conditions of the DAA. The DAA must be signed by the applicant and the relevant Head of Department, or equivalent. If applications include a named collaborator then the collaborator's Institution must sign and submit a separate DAA. A template DAA can be found on the EGA website: <https://www.ebi.ac.uk/ega/sites/ebi.ac.uk.ega/files/documents/Example%20DAA.doc>.
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![Data flow diagram shows the detailed overview of the study design, wet lab experiments and bioinformatics pipelines.](sdata201910-f1){#f1}

![Bioanalyzer (BA) electropherograms of a representative sample (\# Y516) at the first step in the library preparation workflow.\
The figure shows a representative example of the DNA fragment size distribution after sonication. The fragment size peak of this sample is 141 bps.](sdata201910-f2){#f2}

![A representative sample peak is shown in this figure, which illustrates the quality of the amplified library.\
This electropherogram shows a distribution with a DNA fragment size peak of 256 bps for sample Y516.](sdata201910-f3){#f3}

![This figure represents the post-capture quality analysis of the PCR-amplified indexed library from the sample Y516.\
The size peak of this sample was 289 bps, while the average size was 351 bps.](sdata201910-f4){#f4}

###### This table summarizes the brain tissue regions that were used for preparation of genomic DNA, and the final concentrations (ng/ul) of the gDNA samples.

  SAMPLE   BRAIN REGION         Cc
  -------- -------------------- ------
  Y919     occipital cortex     14.5
  Y166     occipital cortex     29.8
  Y645     occipital cortex     15.2
  BI269    occipital cortex     8.39
  Y558     occipital cortex     7.73
  Y591     occipital cortex     5.08
  Y520     occipital cortex     15.3
  Y440     occipital cortex     15.4
  Y426     occipital cortex     5.78
  Y787     occipital cortex     2.1
  Y988     occipital cortex     2.24
  Y482     occipital cortex     20.9
  BIB82    occipital cortex     1.8
  BI370    occipital cortex     6.08
  YA205    occipital cortex     15.3
  Y640     occipital cortex     10
  BI919    occipital cortex     21.6
  YA626    occipital cortex     11.9
  YA29     occipital cortex     5.13
  YB479    occipital cortex     2.23
  YB330    occipital cortex     7.18
  Y928     occipital cortex     6.68
  Y974     occipital cortex     4.38
  Y78      occipital cortex     14.5
  YA762    occipital cortex     2.55
  Y803     cerebellar cortex    18.9
  Y915     cerebellar cortex    18.6
  A438     cerebellar cortex    5.14
  Y880     cerebellar cortex    10.6
  YA243    cerebellar cortex    6.42
  Y967     cerebellar cortex    11.8
  Y726     cerebellar cortex    20.3
  B168     cerebellar cortex    6.46
  Y872     cerebellar cortex    35.5
  Y64      cerebellar cortex    6.1
  Y532     cerebellar cortex    4.91
  Y375     cerebellar cortex    2.44
  Y331     cerebellar cortex    2.25
  Y316     cerebellar cortex    2.51
  Y724     cerebellar cortex    16.1
  Y292     cerebellar cortex    11.8
  Y393     cerebellar cortex    7.23
  Y421     cerebellar cortex    7.42
  Y516     cerebellar cortex    8.77
  Br969    somatomotor cortex   33.2
  Br708    somatomotor cortex   6.11
  Br333    somatomotor cortex   31.3
  Br857    somatomotor cortex   21
  BrA206   somatomotor cortex   17.2

###### This table shows the samples, which were mixed and sequenced together.

  RUN      SAMPLE    TYPE                 BRAIN REGION         INDEX
  -------- --------- -------------------- -------------------- -------
  1        Y919      suicide              occipital cortex     6
  Y166     suicide   occipital cortex     12                   
  Y645     suicide   occipital cortex     4                    
  2        Y375      suicide              cerebellar cortex    12
  Y316     suicide   cerebellar cortex    6                    
  Y393     suicide   cerebellar cortex    4                    
  3        Br333     suicide              somatomotor cortex   6
  Br857    suicide   somatomotor cortex   12                   
  BrA206   suicide   somatomotor cortex   4                    
  4        Y440      suicide              occipital cortex     12
  Y482     suicide   occipital cortex     6                    
  Y558     suicide   occipital cortex     4                    
  5        Y331      suicide              cerebellar cortex    12
  Y724     suicide   cerebellar cortex    6                    
  Y292     suicide   cerebellar cortex    4                    
  6        Y591      suicide              occipital cortex     12
  Y520     suicide   occipital cortex     6                    
  Y787     suicide   occipital cortex     4                    
  7        Y421      suicide              cerebellar cortex    12
  Y516     suicide   cerebellar cortex    6                    
  Y532     suicide   cerebellar cortex    4                    
  8        BIB82     suicide              occipital cortex     12
  Y988     suicide   occipital cortex     6                    
  BI370    suicide   occipital cortex     4                    
  9        BI269     suicide              occipital cortex     12
  Y426     suicide   occipital cortex     6                    
  10       Y803      control              cerebellar cortex    12
  A438     control   cerebellar cortex    6                    
  Y880     control   cerebellar cortex    4                    
  11       YA243     control              cerebellar cortex    12
  Y915     control   cerebellar cortex    6                    
  Y967     control   cerebellar cortex    4                    
  12       Y64       control              cerebellar cortex    12
  Y726     control   cerebellar cortex    6                    
  B168     control   cerebellar cortex    4                    
  13       Y872      control              cerebellar cortex    12
  Br 969   control   somatomotor cortex   4                    
  Br708    control   somatomotor cortex   6                    
  14       YA 205    control              occipital cortex     6
  YB479    control   occipital cortex     12                   
  YB330    control   occipital cortex     4                    
  15       Y928      control              occipital cortex     12
  Y974     control   occipital cortex     6                    
  Y78      control   occipital cortex     4                    
  16       BI919     control              occipital cortex     12
  Y640     control   occipital cortex     6                    
  YA762    control   occipital cortex     4                    
  17       YA626     control              occipital cortex     12
  YA29     control   occipital cortex     6                    

###### Summary table of the quantitative data of sample pools for multiplexed sequencing.

  RUN      SAMPLE    C (nM)^A^   Volume (uL)^B^   C (pg/uL)^C^   C (ng/uL)^D^   C (pg/uL)^E^   C (ng/uL)^F^   Library size^G^   Average size^H^
  -------- --------- ----------- ---------------- -------------- -------------- -------------- -------------- ----------------- -----------------
  1        Y166      199.2       1.51             41654.8        6.4            68000          8.4            343               356
  Y919     124.8     2.40        26722            26300          358                                                            
  Y645     74.5      4.03        16024            21500          366                                                            
  2        Y375      58.781      5.10             12521.73       6.4            8610           4.7            357               350
  Y316     57.027    5.26        11749.08         7200           338                                                            
  Y393     86.632    3.46        18817.57         17100          356                                                            
  3        Br857     111.258     2.70             24428.34       6.4            30700          6.7            375               369
  Br333    54.035    5.55        11475.42         13100          375                                                            
  BrA206   131.504   2.28        27907.52         19500          357                                                            
  4        Y440      39.245      7.64             8191.29        6.4            13300          7.8            352               363
  Y482     25.05     11.98       5482.86          5100           375                                                            
  Y558     75.605    3.97        16207.71         18000          363                                                            
  5        Y331      61.145      4.91             12795.49       6.4            13500          7.2            344               357
  Y724     60.31     4.97        12715.34         20500          362                                                            
  Y292     147.258   2.04        31909.64         23500          365                                                            
  6        Y591      103.25      2.91             22871.87       6.6            19500          7.3            376               374
  Y520     60.856    4.93        12793.51         17400          357                                                            
  Y787     110.566   2.71        25104.72         28100          388                                                            
  7        Y421      75.488      3.97             16289.39       6.5            14200          5.7            355               353
  Y516     61.276    4.90        13104.89         11000          351                                                            
  Y532     69.348    4.33        14934.17         14300          352                                                            
  8        BIB82     139.113     2.16             29501.49       6.0            27400          5.7            350               330
  Y988     68.642    4.37        13380.9          12600          315                                                            
  BI370    43.857    6.84        8660.63          8200           325                                                            
  9        BI269     81.736      5.51             15828.78       6.0            11800          4.4            313               329
  Y426     54.168    8.31        11230            8210           345                                                            
  10       Y803      43.374      6.92             8970.21        6.4            6420           4.8            341               358
  A438     135.98    2.21        30004            22100          373                                                            
  Y880     115.546   2.60        24433.7          19200          359                                                            
  11       YA243     49.12       6.11             10428.1        6.4            9450           5.7            371               361
  Y915     48.499    6.19        10605            8720           363                                                            
  Y967     123.886   2.42        26052            25000          349                                                            
  12       Y64       139.449     2.15             29738.07       6.4            30500          7.1            357               357
  Y726     112.212   2.67        23744            28300          357                                                            
  B168     135.267   2.22        29033.01         32100          357                                                            
  13       Y872      149.778     2.00             31377.06       6.4            28100          6.5            350               361
  Br708    116.782   2.57        24462.06         33500          355                                                            
  Br969    100.18    2.99        21967.36         17400          377                                                            
  14       YB479     127.498     2.35             27282.84       6.3            25500          6.1            356               350
  YA205    61.118    4.91        12889.7          10030          354                                                            
  YB330    95.388    3.15        19830.54         23900          340                                                            
  15       Y928      67.261      4.46             14431.43       6.4            14700          6.9            358               356
  Y974     99.194    3.02        21249.16         24900          367                                                            
  Y78      90.024    3.33        18648            19800          343                                                            
  16       BI919     113.104     2.65             24609.88       6.4            24100          7.5            377               360
  Y640     161.115   1.86        34615.56         48300          369                                                            
  YA762    119.56    2.51        24368.42         28200          335                                                            
  17       YA626     94.57       4.76             20189.16       6.5            22400          6.6            352               360
  YA29     136.8     3.29        29716.84         28000          368                                                            

###### Summary of the technical replicates.

  PATIENT            BRAIN REGION   
  ------------------ -------------- --------------------
  \#194              control        occipital cortex
  occipital cortex                  
  \#230              control        somatomotor cortex
  occipital cortex                  
  \#148              suicide        occipital cortex
  occipital cortex                  
  \#143              suicide        occipital cortex
  occipital cortex                  
  \#158              suicide        cerebellar cortex
  occipital cortex                  

###### Quality control data and statistics from whole-exome sequencing.

  Sample ID   no. reads   mapped reads (%)   duplicates (%)   statistics of the analyzed region (Sure Select V5 All Exon Plus UTR, 15 bp added)                                                         
  ----------- ----------- ------------------ ---------------- ----------------------------------------------------------------------------------- -------- ------- --------- -------- -------- -------- --------
  A438        138452577   99.92%             5.26%            92.01%                                                                              190.8    67.7    119.9     99.60%   99.20%   97.60%   90.60%
  B168        140611220   99.94%             2.28%            92.93%                                                                              184.2    55.3    134.5     99.30%   98.60%   96.40%   88.80%
  BI269\*     187542878   99.96%             9.18%            0.926137                                                                            157.93   45.71   168.597   99.10%   98.40%   96.40%   90.50%
  BI370\*     138284674   99.96%             8.02%            0.925547                                                                            159.99   48.74   125.946   98.90%   97.80%   94.80%   85.50%
  BI919\*     97057952    99.94%             3.96%            0.901908                                                                            183.16   63.17   88.512    99.10%   97.70%   93.30%   78.00%
  BIB82       130560882   99.94%             3.30%            92.36%                                                                              180.8    57.1    122.1     99.50%   99.00%   97.20%   89.90%
  Br333       93171478    99.95%             6.63%            93.12%                                                                              190.6    68.6    80.7      99.00%   97.70%   93.10%   76.40%
  Br708       178033001   99.94%             3.25%            93.01%                                                                              177.5    54.2    166.6     99.50%   99.10%   98.00%   94.20%
  Br857       144136294   99.96%             3.43%            92.79%                                                                              186.4    64.2    133.5     99.40%   98.90%   97.20%   90.80%
  Br969       106686550   99.92%             5.23%            91.83%                                                                              185.9    68.0    95.7      99.30%   98.60%   95.90%   84.80%
  BrA206      80177041    99.96%             3.44%            93.32%                                                                              185.3    62.6    72.9      98.80%   97.20%   91.40%   71.70%
  Y166        76810758    99.96%             4.51%            93.30%                                                                              174.9    52.4    69.8      99.10%   97.60%   91.80%   71.30%
  Y292        95054488    99.81%             2.32%            92.12%                                                                              180.9    57.4    88.5      99.20%   98.10%   94.30%   80.00%
  Y316        87607856    99.95%             9.49%            92.09%                                                                              174.1    56.7    74.9      99.20%   98.20%   93.90%   76.60%
  Y331        96374496    99.82%             7.61%            90.97%                                                                              179.4    57.5    85.0      99.30%   98.40%   94.80%   80.30%
  Y375        99837105    99.93%             7.35%            91.82%                                                                              181.6    63.8    86.9      99.40%   98.60%   95.60%   82.20%
  Y393        126108409   99.94%             6.30%            93.40%                                                                              189.4    59.8    110.9     99.60%   99.00%   97.00%   88.10%
  Y421        100073380   99.93%             5.74%            92.01%                                                                              186.1    58.5    89.2      99.20%   98.30%   94.80%   81.10%
  Y426        165152957   99.94%             24.86%           90.08%                                                                              175.2    60.6    113.5     99.60%   99.20%   97.90%   91.50%
  Y440\*      120135303   99.78%             13.84%           0.900957                                                                            177.41   62.88   97.494    99.40%   98.80%   96.30%   85.80%
  Y482        83982287    99.75%             21.33%           90.80%                                                                              188.2    70.9    59.7      99.10%   97.60%   91.10%   67.20%
  Y516        105766222   99.92%             6.94%            92.24%                                                                              183.6    56.0    93.3      98.80%   97.50%   93.40%   79.60%
  Y520        116261151   99.80%             5.07%            91.62%                                                                              175.6    58.4    106.2     99.20%   98.30%   95.50%   85.10%
  Y532        104607488   99.92%             5.72%            91.77%                                                                              185.9    56.8    93.6      99.40%   98.60%   95.50%   82.80%
  Y558        99200163    99.79%             4.78%            91.02%                                                                              180.2    60.6    89.0      99.00%   97.70%   93.70%   79.80%
  Y591        81128182    99.79%             3.15%            91.46%                                                                              189.9    67.4    74.3      99.20%   98.00%   93.10%   74.50%
  Y64         133401783   99.93%             2.80%            92.41%                                                                              180.0    58.0    127.8     99.40%   98.80%   96.60%   88.50%
  Y640        129387141   99.94%             2.19%            89.53%                                                                              176.1    55.8    125.0     99.40%   98.70%   96.40%   88.10%
  Y645        114470684   99.95%             9.44%            93.06%                                                                              180.0    61.7    96.1      99.50%   98.80%   96.30%   85.30%
  Y724        124302299   99.84%             5.34%            92.01%                                                                              176.0    59.8    114.0     99.30%   98.60%   96.30%   87.60%
  Y726        101306831   99.93%             3.54%            91.98%                                                                              177.7    60.4    94.1      99.30%   98.40%   95.20%   82.90%
  Y78         89614381    99.94%             5.49%            90.99%                                                                              176.9    56.5    79.4      98.90%   97.40%   92.10%   74.20%
  Y787        114795165   99.80%             3.63%            92.68%                                                                              197.0    71.2    103.7     99.50%   98.90%   96.70%   87.20%
  Y803        120331211   99.93%             12.18%           91.54%                                                                              176.2    58.9    100.5     99.40%   98.70%   96.20%   86.00%
  Y872        141008850   99.93%             2.49%            92.74%                                                                              175.4    52.1    137.4     99.30%   98.60%   96.50%   89.10%
  Y880        110514415   99.90%             4.95%            92.46%                                                                              181.6    65.7    85.9      99.20%   98.10%   93.90%   78.60%
  Y915        101630477   99.88%             12.02%           93.19%                                                                              192.2    65.7    82.7      99.30%   98.40%   94.80%   79.80%
  Y919        88647901    99.96%             3.69%            93.03%                                                                              179.2    57.4    80.1      99.30%   98.20%   93.90%   77.50%
  Y928        94852671    99.94%             4.20%            91.06%                                                                              182.6    61.4    86.2      98.90%   97.40%   92.60%   76.90%
  Y967        117471985   99.93%             3.69%            93.49%                                                                              179.6    58.5    108.5     99.50%   98.80%   96.40%   86.80%
  Y974        119874575   99.94%             4.46%            89.84%                                                                              178.6    61.7    109.1     99.60%   98.90%   96.70%   87.50%
  Y988        127546449   99.96%             5.33%            92.30%                                                                              157.7    46.3    120.2     98.70%   97.50%   93.90%   83.30%
  YA205       96160167    99.95%             7.07%            90.93%                                                                              177.5    61.1    84.7      99.20%   98.10%   93.80%   78.30%
  YA243       129654716   99.92%             9.35%            93.46%                                                                              186.4    69.1    110.0     99.10%   98.10%   94.80%   83.50%
  YA29        170816106   99.91%             2.96%            83.51%                                                                              182.1    55.8    161.4     99.30%   98.70%   97.20%   92.20%
  YA626       195722635   99.91%             6.58%            84.44%                                                                              179.3    49.7    175.8     99.60%   99.10%   97.90%   93.90%
  YA762\*     107955782   99.95%             4.02%            0.89896                                                                             168.69   49.99   101.205   99.20%   98.30%   95.30%   84.20%
  YB330       106184066   99.94%             4.54%            91.56%                                                                              178.1    51.5    98.6      99.00%   98.00%   94.70%   82.90%
  YB479       105205966   99.94%             2.95%            90.97%                                                                              181.0    56.4    98.6      99.40%   98.50%   95.30%   83.10%
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